HEPATITIS TESTING GUIDE Alegent Health Reference Laboratory

Total Page:16

File Type:pdf, Size:1020Kb

HEPATITIS TESTING GUIDE Alegent Health Reference Laboratory HEPATITIS TESTING GUIDE Alegent Health Reference Laboratory Test Name NextGen Alegent Test Directory Test Description (Cerner) Orderable Name Number Order when patient has had clinical acute hepatitis of unknown origin for less than 6 months. Hepatitis Panel, Hepatitis Panel Panel includes; Hep A virus, IgM, Hepatitis Panel ARUP Acute with reflex to Hepatitis Panel, Acute with reflex Hep B virus Core antibody, IgM, Acute (0020457) HBsAg to HBsAg Confirmation Hep B virus Surface antigen with reflex to confirmation, Hep C virus antibody by CIA ARUP Order this assay when acute Hepatitis A infection is suspected. Hepatitis A Ab IgM Hep A Ab IgM Hepatitis A, IgM (0020093) Positive HAV IgM shows current or recent infection. Order only when assessing immunity for HAV from either Hepatitis A Hepatitis A Hepatitis A Virus Antibodies ARUP vaccination or previous infection. Do not use to diagnose acute antibody, total (IgG Antibody IgG & (Total) (0020591) infection. Total assay detects both IgG and IgM antibodies but and IgM IgM does not differentiate between them. Order when patient has had clinical acute hepatitis of unknown origin for less than 6 months. Positivity indicates recent Hepatitis B core Ab Hep B Core Ab Hepatitis B Virus Core Antibody, ARUP infection with hepatitis B virus, with onset < 6 months. It's IgM IgM IgM (0020092) presence indicates acute infection. In some cases, hepatitis B core IgM antibody may be the only specific marker for the diagnosis of acute infection with hepatitis B virus. This assay does not distinguish between Total B core antibody IgG and IgM detected before or at the onset of symptoms; Hepatitis B Core Hepatitis B core Hepatitis B Virus Core Antibodies ARUP however, such reactivity can persist for years after illness, and Antibody IgG & antibody (Total) (0020091) may even outlast anti-HBs. Occasionally Hepatitis B core IgM antibody may be the only marker of either current or past Hepatitis B infection. Used to detect immunity to Hepatitis B virus. The presence of anti-HBs is generally interpreted as indicating recovery and immunity from hepatitis B virus infection. Anti-HBs also Hepatitis B surface Hepatitis B Surface Hepatitis B surface antibody Alegent develops in a person who has been successfully vaccinated antibody Antibody against hepatitis B. To determine immune status as ≥10 mIU/mL as per CDC guidelines, please order Hepatitis B Surface Antibody, Quantitative. A protein on the surface of hepatitis B virus; it can be detected in high levels in serum during acute or chronic hepatitis B virus Hepatitis B surface Hepatitis B Surface Hepatitis B surface antigen Alegent infection. The presence of HBsAg indicates that the person is antigen Antigen infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. Surface antigen usually appears in the serum after an incubation period of 1 to 6 months following exposure to HBV and peaks shortly after onset of symptoms. It typically disappears within 1 to 3 months. Persistence of HBsAg for greater than 6 months is a prognostic indicator of chronic Hepatitis B infection. Chronic carriers will persist in producing detectable HBV. Hepatitis B Virus DNA Patients with chronic liver disease of unknown origin most Hepatitis B viral Hepatitis B viral ARUP Ultrasensitive Quatitative Real- commonly have HBV that is detected by viral DNA testing. DNA, Quantitative DNA, Quantitative (0056025) Time PCR Quantitative measurement of HBV viral DNA may be used to monitor progression of disease. Anti-HBe in the blood following exposure to the Hepatitis B Hepatitis Be Hepatitis Be ARUP Hepatitis Be Virus Antibody virus suggests a good prognosis for patients with Hepatitis B antibody Antibody (0020095) infection. Hepatitis Be ARUP Persistence of HBeAg for greater than 6 months is a prognostic Hepatitis Be antigen Hepatitis Be Virus Antigen Antigen (0020094) indicator of a chronic hepatitis B virus carrier state. Hepatitis C Virus (HCV) is the major cause of hepatitis. Approximately 1% of blood donors are seropositive for anti- HCV. The clinical symptoms of a HCV infection are variable. Hepatitis C antibody Hep C Ab Hepatitis C Virus Antibody Alegent Exposure to HCV results in a chronic infection in 50 to 80% of cases. The "window" between infection and seroreactivity is highly variable, up to 12 months. Hepatitis C Hepatitis C Hepatitis C Virus Genotyping by ARUP Assess length of treatment required and likelihood of response genotyping Genotyping PCR & Sequencing (0055593) (used as baseline) Confirm active hepatitis C virus (HCV) infection. Document Hepatitis C RNA Hepatitis C RNA Hepatitis C Virus RNA Qualitative ARUP rapid (RVR) and early (EVR) virologic response. Guide PCR Qualitative PCR Qualitative PCR (0098264) duration of antiviral therapy. Confirm resolution of infection and sustained virologic response (SVR) Confirm active hepatitis C virus (HCV) infection. Document rapid (RVR) and early (EVR) virologic response. Guide duration of antiviral therapy. Confirm resolution of infection Hepatitis C RNA Hepatitis C RNA Hepatitis C Virus RNA ARUP and sustained virologic response (SVR) PCR Quantitative PCR Quantitative Quantitative, Real-Time PCR (0098268) Establish viral load at baseline; monitor viral load during therapy; determine duration of treatment; assess likelihood of non-response during treatment Hepatitis C RNA Miscellaneous Hepatitis C Virus RNA PCR ARUP Establish viral load and genotype at baseline; determine duration Serology Quantitative by Real-Time PCR Quantitative/Reflex (2002685) of treatment and likelihood of response with Reflex to Genotype genotyping November 2012 .
Recommended publications
  • Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 6763-6767, September 1989 Medical Sciences Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus (adenovirus animal model/adenovirus-vectored vacdnes) MICHAEL D. LUBECK*, ALAN R. DAVIS*, MURTY CHENGALVALA*, ROBERT J. NATUK*, JOHN E. MORIN*, KATHERINE MOLNAR-KIMBER*, BRUCE B. MASON*, BHEEM M. BHAT*, SATOSHI MIZUTANI*, PAUL P. HUNG*, AND ROBERT H. PURCELLO *Wyeth-Ayerst Research, Biotechnology and Microbiology Division, P.O. Pox 8299, Philadelphia, PA 19101; and tLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 Contributed by Robert H. Purcell, May 30, 1989 ABSTRACT As a major cause of acute and chronic liver which, because oftheir wide prior usage, are good candidates disease as well as hepatocellular carcinoma, hepatitis B virus as vectors. Other less well-characterized small animal models (HBV) continues to pose significant health problems world- for human adenoviruses have been occasionally reported wide. Recombinant hepatitis B vaccines based on adenovirus (11-13) but are likewise nonpermissive for Ad4 and Ad7 vectors have been developed to address global needs for infections (unpublished data). An early study of animal effective control of hepatitits B infection. Although consider- species including nonhuman primates indicated that human able progress has been made in the construction ofrecombinant adenoviruses do not induce acute respiratory disease in adenoviruses that express large amounts of HBV gene prod- monkeys or chimpanzees following intranasal inoculations ucts, preclinical immunogenicity and efficacy testing of candi- (14). Serological data, however, indicated that such experi- date vaccines has remained difficult due to the lack ofa suitable mental infections occasionally induced anti-adenovirus anti- animal model.
    [Show full text]
  • Hepatitis B Fast Facts Everything You Need to Know in 2 Minutes Or Less!
    Hepatitis B Foundation Cause for a Cure www.hepb.org Hepatitis B Fast Facts Everything you need to know in 2 minutes or less! Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV) that attacks liver cells and can lead to liver failure, cirrhosis (scarring) or cancer of the liver. The virus is transmitted through contact with blood and bodily fluids that contain blood. Most people are able to fight off the hepatitis B infection and clear the virus from their blood. This may take up to six months. While the virus is present in their blood, infected people can pass the virus on to others. Approximately 5-10% of adults, 30-50% of children, and 90% of babies will not get rid of the virus and will develop chronic infection. Chronically infected people can pass the virus on to others and are at increased risk for liver problems later in life. The hepatitis B virus is 100 times more infectious than the AIDS virus. Yet, hepatitis B can be pre- vented with a safe and effective vaccine. For the 400 million people worldwide who are chronically infected with hepatitis B, the vaccine is of no use. However, there are promising new treatments for those who live with chronic hepatitis B. In the World: • This year alone, 10 to 30 million people will become infected with the hepatitis B virus (HBV). • The World Health Organization estimates that 400 million people worldwide are already chronically infected with hepatitis B.
    [Show full text]
  • Prevention & Control of Viral Hepatitis Infection
    Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action © World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Table of contents Disease burden 02 What is viral hepatitis? 05 Prevention & control: a tailored approach 06 Global Achievements 08 Remaining challenges 10 World Health Assembly: a mandate for comprehensive prevention & control 13 WHO goals and strategy
    [Show full text]
  • The Role of Hepatitis C Virus in Hepatocellular Carcinoma U
    Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma U. Hibner, D. Gregoire To cite this version: U. Hibner, D. Gregoire. Viruses in cancer cell plasticity: the role of hepatitis C virus in hepato- cellular carcinoma. Contemporary Oncology, Termedia Publishing House, 2015, 19 (1A), pp.A62–7. 10.5114/wo.2014.47132. hal-02187396 HAL Id: hal-02187396 https://hal.archives-ouvertes.fr/hal-02187396 Submitted on 2 Jun 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike| 4.0 International License Review Viruses are considered as causative agents of a significant proportion of human cancers. While the very Viruses in cancer cell plasticity: stringent criteria used for their clas- sification probably lead to an under- estimation, only six human viruses the role of hepatitis C virus are currently classified as oncogenic. In this review we give a brief histor- in hepatocellular carcinoma ical account of the discovery of on- cogenic viruses and then analyse the mechanisms underlying the infectious causes of cancer. We discuss viral strategies that evolved to ensure vi- Urszula Hibner1,2,3, Damien Grégoire1,2,3 rus propagation and spread can alter cellular homeostasis in a way that increases the probability of oncogen- 1Institut de Génétique Moléculaire de Montpellier, CNRS, UMR 5535, Montpellier, France ic transformation and acquisition of 2Université Montpellier 2, Montpellier, France stem cell phenotype.
    [Show full text]
  • Rational Engineering of HCV Vaccines for Humoral Immunity
    viruses Review To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity Felicia Schlotthauer 1,2,†, Joey McGregor 1,2,† and Heidi E Drummer 1,2,3,* 1 Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia; [email protected] (F.S.); [email protected] (J.M.) 2 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia 3 Department of Microbiology, Monash University, Clayton, VIC 3800, Australia * Correspondence: [email protected]; Tel.: +61-392-822-179 † These authors contributed equally to this work. Abstract: Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that gen- erate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development. Keywords: glycoprotein E2; vaccine development; humoral immunity Citation: Schlotthauer, F.; McGregor, J.; Drummer, H.E To Include or 1. Introduction Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. The development of direct-acting antiviral agents (DAA) with their ability to cure Viruses 2021, 13, 805. https:// infection in >95% of those treated was heralded as the key to eliminating hepatitis C globally.
    [Show full text]
  • Hepatitis B? HEPATITIS B Hepatitis B Is a Contagious Liver Disease That Results from Infection with the Hepatitis B Virus
    What is Hepatitis B? HEPATITIS B Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop Are you at risk? an “acute” infection, which can range in severity from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Acute Hepatitis B refers to the first 6 months after someone is exposed to the Hepatitis B virus. Some people are able to fight the infection and clear the virus. For others, the infection remains and leads to a “chronic,” or lifelong, illness. Chronic Hepatitis B refers to the illness that occurs when the Hepatitis B virus remains in a person’s body. Over time, the infection can cause serious health problems. How is Hepatitis B spread? Hepatitis B is usually spread when blood, semen, or other body fluids from a person infected with the Hepatitis B virus enter the body of someone who is not infected. This can happen through having sex with an infected partner; sharing needles, syringes, or other injection drug equipment; or from direct contact with the blood or open sores of an infected person. Hepatitis B can also be passed from an infected mother to her baby at birth. Who should be tested for Hepatitis B? Approximately 1.2 million people in the United States and 350 million people worldwide have Hepatitis B. Testing for Hepatitis B is recommended for certain groups of people, including: Most are unaware of their infection. ■ People born in Asia, Africa, and other regions with moderate or high rates Is Hepatitis B common? of Hepatitis B (see map) Yes.
    [Show full text]
  • Hepatitis A, B, and C: Learn the Differences
    Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV.
    [Show full text]
  • Understanding Human Astrovirus from Pathogenesis to Treatment
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 6-2020 Understanding Human Astrovirus from Pathogenesis to Treatment Virginia Hargest University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Diseases Commons, Medical Sciences Commons, and the Viruses Commons Recommended Citation Hargest, Virginia (0000-0003-3883-1232), "Understanding Human Astrovirus from Pathogenesis to Treatment" (2020). Theses and Dissertations (ETD). Paper 523. http://dx.doi.org/10.21007/ etd.cghs.2020.0507. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Understanding Human Astrovirus from Pathogenesis to Treatment Abstract While human astroviruses (HAstV) were discovered nearly 45 years ago, these small positive-sense RNA viruses remain critically understudied. These studies provide fundamental new research on astrovirus pathogenesis and disruption of the gut epithelium by induction of epithelial-mesenchymal transition (EMT) following astrovirus infection. Here we characterize HAstV-induced EMT as an upregulation of SNAI1 and VIM with a down regulation of CDH1 and OCLN, loss of cell-cell junctions most notably at 18 hours post-infection (hpi), and loss of cellular polarity by 24 hpi. While active transforming growth factor- (TGF-) increases during HAstV infection, inhibition of TGF- signaling does not hinder EMT induction. However, HAstV-induced EMT does require active viral replication.
    [Show full text]
  • Host Cell Functions in Vesicular Stomatitis Virus Replication Phat X
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Papers in Veterinary and Biomedical Science Veterinary and Biomedical Sciences, Department of 2016 Host Cell Functions In Vesicular Stomatitis Virus Replication Phat X. Dinh University of Nebraska - Lincoln Anshuman Das University of Nebraska-Lincoln Asit K. Pattnaik University of Nebraska - Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons, Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and Pathobiology Commons Dinh, Phat X.; Das, Anshuman; and Pattnaik, Asit K., "Host Cell Functions In Vesicular Stomatitis Virus Replication" (2016). Papers in Veterinary and Biomedical Science. 237. https://digitalcommons.unl.edu/vetscipapers/237 This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Published in Biology and Pathogenesis of Rhabdo and Filoviruses Copyright © 2016 World Scientific Publishing Co Pte Ltd digitalcommons.unl.edu HOST CELL FUNCTIONS IN VESICULAR STOMATITIS VIRUS REPLICATION Phat X. Dinh, Anshuman Das, and Asit K. Pattnaik School of Veterinary Medicine and Biomedical Sciences and the Nebraska Center for Virology, University of Nebraska-Lincoln, 109 Morrison Life Science Research Center, 4240 Fair Street, Lincoln, * Nebraska 68583, USA E-mail: [email protected] Summary Vesicular stomatitis virus (VSV), the prototypic rhabdovirus, has been used as an excellent paradigm for understanding the mechanisms of virus replication, pathogenesis, host response to virus infection and also for myriads of studies on cellular and molecular biology.
    [Show full text]
  • The Role of Hepatitis C Virus in Hepatocellular Carcinoma A63
    Review Viruses are considered as causative agents of a significant proportion of human cancers. While the very Viruses in cancer cell plasticity: stringent criteria used for their clas- sification probably lead to an under- estimation, only six human viruses the role of hepatitis C virus are currently classified as oncogenic. In this review we give a brief histor- in hepatocellular carcinoma ical account of the discovery of on- cogenic viruses and then analyse the mechanisms underlying the infectious causes of cancer. We discuss viral strategies that evolved to ensure vi- Urszula Hibner1,2,3, Damien Grégoire1,2,3 rus propagation and spread can alter cellular homeostasis in a way that increases the probability of oncogen- 1Institut de Génétique Moléculaire de Montpellier, CNRS, UMR 5535, Montpellier, France ic transformation and acquisition of 2Université Montpellier 2, Montpellier, France stem cell phenotype. We argue that 3Université Montpellier 1, Montpellier, France a useful way of analysing the conver- gent characteristics of viral infection and cancer is to examine how viruses affect the so-called cancer hallmarks. Introduction This view of infectious origin of cancer It is estimated that close to 20% of human cancers are due to infections is illustrated by examples from hep- atitis C infection, which is associated with known pathogens, mainly with viruses [1]. Given the difficulties in un- with a high proportion of hepatocellu- ambiguously assigning their causative role [2] and the fast rate of discovery lar carcinoma. of new viruses [3], it is likely a conservative estimate. Different pathogens are associated with increased cancer risk. One of the Key words: viruses, cancer cell plas- first identified cancer-causing infectious disease was schistosomiasis, ini- ticity, HCV, hepatocellular carcinoma.
    [Show full text]
  • Revisiting the Elusive Hepatitis C Vaccine
    Editorial Revisiting the Elusive Hepatitis C Vaccine Stephen M. Todryk 1,2,* , Margaret F. Bassendine 2,* and Simon H. Bridge 1,2,* 1 Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK 2 Translational & Clinical Research Institute, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK * Correspondence: [email protected] (S.M.T.); [email protected] (M.F.B.); [email protected] (S.H.B.) The impactful discovery and subsequent characterisation of hepatitis C virus (HCV), an RNA virus of the flavivirus family, led to the awarding of the 2020 Nobel Prize in Physiology or Medicine to Harvey J. Alter, Michael Houghton and Charles M. Rice [1]. However, despite the significant advances recognised by this Nobel prize, an effective HCV vaccine remains elusive. The recent success of vaccines against SARS-CoV-2, developed with unprecedented speed, has shone a bright light on the vaccination process for protection against viral threats and may provide renewed impetus for the development of vaccines for other viruses. HCV infection remains a major global health problem as approximately three quarters of those infected develop chronic infection, leading to morbidity and mortality due to progressive liver fibrosis, cirrhosis and cancer. The World Health Organization (WHO) estimates that 71.1 million people are living with chronic HCV, resulting in over 400,000 deaths every year. In 2016, the WHO adopted a global strategy with the aim of eliminating viral hepatitis as a public health problem, comprising targets to reduce new viral hepatitis infections by 90% and reduce deaths due to viral hepatitis by 65% by 2030.
    [Show full text]
  • Hepatitis B Factsheet: COVID-19 and Hep B
    Hepatitis B factsheet: COVID-19 and hep B For more information about anything in this factsheet, phone the Hepatitis Infoline on 1800 803 990 or go to www.hep.org.au COVID-19 and hep B Frequently Asked Questions (FAQ) There’s so much information swirling around these days as we deal with the changing world around us due to COVID-19. There’s lots of incorrect information and it’s easy to be overwhelmed and confused. On this page, we’ll try to clear some things up. It is important that information is helpful, clear, and checked and confirmed by experts. Please share the following information – it comes from health and medical specialists. COVID-19 is an acronym that stands for COronaVIrus Disease 2019. You might hear it called coronavirus, corona, SARS-CoV-2, or even rona. We’ll call it COVID-19 or coronavirus in this FAQ but all these terms are essentially talking about the same thing and we’ll explain them at the bottom. You’ll also hear new or unfamiliar terms like “social distancing,” “physical distancing,” “self-isolation,” and “quarantine”. These terms and what they actually mean can become confusing so we’ve including a glossary at the bottom of this FAQ. This virus has only been known about since around December 2019 so it’s all very new, information changes quickly, and we’re all learning day-by-day and week-by-week. Compare COVID-19 to hep B which we’ve known about since the 1980s and hep B even earlier in the 1960s! We’ll regularly update this page as new information comes to light.
    [Show full text]